Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management
Stockholm, April 23, 2024 –Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions. KKR and Impilo will work together with Immedica’s management team to support Immedica’s continued growth, including the launch of the recently approved ultra-orphan drug Loargys, additional pipeline assets, continued in-licensing, M&A and expansion into new territories.